๐ฐ Early Access Program News
Page 39 - Early Access Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Early Access Program. Real-time updates on events, politics, business and more.
December 8, 2021
Quick Take: Ford Motor Company, a global auto manufacturer and longtime innovator in the automotive industry, today announced the launch of VIIZR, a...
December 2, 2021
River Falls, Wisconsin (PRWEB) December 02, 2021 -- Eurofins BioDiagnostics, Inc. (EBDI), a global leader in agriculture and genomics testing, announces the
December 1, 2021
Comments on results from HERACLES Phase 2 trial and from early access program (EAP) in gastrointestinal acute Graft-vs-Host-Disease (GI aGvHD) Company to also provide a corporate update during
December 1, 2021
Comments on results from HERACLES Phase 2 trial and from early access program (EAP) in gastrointestinal acute Graft-vs-Host-Disease (GI aGvHD)Company to also provide a corporate update during webcastLYON, France--(BUSINESS WIRE)--$MAAT--MaaT Pharma (EURONEXT: MAAT - the โCompanyโ), a French clinical-stage biotech an...
December 1, 2021
Comments on results from HERACLES Phase 2 trial and from early access program (EAP) in gastrointestinal acute Graft-vs-Host-Disease (GI aGvHD)Company to also provide a corporate update during webcastLYON, France--(BUSINESS WIRE)--$MAAT--Regulatory News:MaaT Pharma (EURONEXT: MAAT - the โCompanyโ), a French clinical-...
November 30, 2021
New Appointment Significantly Expands SaaS Sales Leadership and Expertise for BlustreamWORCESTER, MA / ACCESSWIRE / November 30, 2021 / Blustream.io, the leading after-sale product engagement platform
November 26, 2021
Victoria, British Columbia--(Newsfile Corp. - November 26, 2021) - Plurilock Security Inc. (TSXV: PLUR) (OTCQB: PLCKF) and related subsidiaries ("Plurilock" or the "Company"), an identity-centric cybersecurity
November 3, 2021
Early Access to New Platform Allows Companies Selling Physical Products to Leverage Product Usage DataWORCESTER, MA / ACCESSWIRE / November 3, 2021 / Blustream.io, the leading after-sale product engagement
November 2, 2021
Merus participated in a Type B meeting with the FDA regarding its zenocutuzumab development program and obtained alignment with FDA on registration approach for a potential tumor agnostic indicationMerus
November 2, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation.